Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease, New England Journal of Medicine, vol.367, issue.9, pp.795-804, 2012. ,
DOI : 10.1056/NEJMoa1202753
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474597/pdf
Analysis of recent failures of disease modifying therapies in Alzheimer???s disease suggesting a new methodology for future studies, Expert Review of Neurotherapeutics, vol.38, issue.1, pp.7-16, 2017. ,
DOI : 10.1126/scitranslmed.aaa2512
Improved discrimination of AD patients using ??-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, issue.8, pp.1555-1562, 1999. ,
DOI : 10.1212/WNL.52.8.1555
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, The Lancet Neurology, vol.15, issue.7, pp.673-684, 2016. ,
DOI : 10.1016/S1474-4422(16)00070-3
The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease, Medical Clinics of North America, vol.97, issue.3, pp.369-376, 2013. ,
DOI : 10.1016/j.mcna.2012.12.012
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer???s disease, Brain, vol.134, issue.1, pp.301-317, 2011. ,
DOI : 10.1093/brain/awq349
Early detection of Alzheimer's disease using PiB and FDG PET, Neurobiology of Disease, vol.72, pp.117-122, 2014. ,
DOI : 10.1016/j.nbd.2014.05.001
Cerebrospinal fluid analysis detects cerebral amyloid-?? accumulation earlier than positron emission tomography, Brain, vol.139, issue.4, pp.1226-1236, 2016. ,
DOI : 10.1093/brain/aww015
URL : https://academic.oup.com/brain/article-pdf/139/4/1226/17348994/aww015.pdf
Plasma tau in Alzheimer disease, Neurology, vol.87, issue.17, pp.1827-1835, 2016. ,
DOI : 10.1212/WNL.0000000000003246
URL : http://www.neurology.org/content/87/17/1827.full.pdf
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.8, pp.131-138, 2017. ,
DOI : 10.1016/j.dadm.2017.04.002
CSF markers for incipient Alzheimer's disease, The Lancet Neurology, vol.2, issue.10, pp.605-613, 2003. ,
DOI : 10.1016/S1474-4422(03)00530-1
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, The Lancet Neurology, vol.5, issue.3, pp.228-234, 2006. ,
DOI : 10.1016/S1474-4422(06)70355-6
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, vol.134, issue.9, pp.2456-2477, 2011. ,
DOI : 10.1093/brain/awr179
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment, JAMA, vol.302, issue.4, pp.385-393, 2009. ,
DOI : 10.1001/jama.2009.1064
URL : http://jama.jamanetwork.com/data/journals/jama/4473/joc90069_385_393.pdf
APOE and Alzheimer disease: a major gene with semi-dominant inheritance, Molecular Psychiatry, vol.67, issue.9, p.903, 2011. ,
DOI : 10.1056/NEJMoa0809578
URL : http://www.nature.com/mp/journal/v16/n9/pdf/mp201152a.pdf
Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia, Alzheimer's & Dementia, vol.2, issue.1, pp.36-42, 2004. ,
DOI : 10.1016/j.jalz.2005.11.002
Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study, Neurology, vol.46, issue.3, pp.678-681, 1996. ,
DOI : 10.1212/WNL.46.3.678
Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease, Neurology, vol.52, issue.1, pp.91-100, 1999. ,
DOI : 10.1212/WNL.52.1.91
Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry, Journal of Neurology, Neurosurgery & Psychiatry, vol.73, issue.6, pp.657-664, 2002. ,
DOI : 10.1136/jnnp.73.6.657
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature, Journal of Neuropathology & Experimental Neurology, vol.71, issue.5, pp.362-381, 2012. ,
DOI : 10.1097/NEN.0b013e31825018f7
Phases of A??-deposition in the human brain and its relevance for the development of AD, Neurology, vol.58, issue.12, pp.1791-1800, 2002. ,
DOI : 10.1212/WNL.58.12.1791
Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD, Current Alzheimer Research, vol.7, issue.4, p.280, 2010. ,
DOI : 10.2174/156720510791162340
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.239-259, 1991. ,
DOI : 10.1007/978-3-642-70644-8_2
The biochemical pathway of neurofibrillary degeneration in aging and ,
Alzheimer's disease, The Lancet, vol.368, issue.9533, pp.387-403, 2006. ,
DOI : 10.1016/S0140-6736(06)69113-7
URL : https://hal.archives-ouvertes.fr/hal-01098836
Recent insights into the molecular genetics of dementia, Trends in Neurosciences, vol.32, issue.8, p.451, 2009. ,
DOI : 10.1016/j.tins.2009.05.005
Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons, European Journal of Human Genetics, vol.39, issue.5, p.710, 2016. ,
DOI : 10.1007/s00415-013-7160-3
URL : https://hal.archives-ouvertes.fr/hal-01431285
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, Nature Genetics, vol.34, issue.10, p.1088, 2009. ,
DOI : 10.1212/WNL.56.1.127
URL : http://www.nature.com/ng/journal/v45/n6/pdf/ng0613-712a.pdf
Associated with the Risk of Alzheimer's Disease, New England Journal of Medicine, vol.368, issue.2, 2013. ,
DOI : 10.1056/NEJMoa1211103
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in ,
The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers, J. Alzheimers Dis, vol.30, pp.847-856, 2012. ,
Genotype-phenotype relationships of presenilin-1 mutations in ,
Variable phenotype of Alzheimer's disease with spastic paraparesis, J ,
Ataxic variant of Alzheimer's disease caused by Pro117Ala PSEN1 mutation, Journal of Neurology, Neurosurgery & Psychiatry, vol.78, issue.12 ,
DOI : 10.1136/jnnp.2007.123026
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095586/pdf
Amyloid Angiopathy and Variability in Amyloid ?? Deposition Is Determined by Mutation Position in Presenilin-1-Linked Alzheimer???s Disease, The American Journal of Pathology, vol.158, issue.6, p.2165, 2001. ,
DOI : 10.1016/S0002-9440(10)64688-3
Alzheimer???s disease phenotypes and genotypes associated with mutations in presenilin 2, Brain, vol.133, issue.4, p.1143, 2010. ,
DOI : 10.1093/brain/awq033
Amyloid deposition as the central event in the aetiology of Alzheimer's disease, Trends in Pharmacological Sciences, vol.12, pp.383-388, 1991. ,
DOI : 10.1016/0165-6147(91)90609-V
APP at a glance, Journal of Cell Science, vol.120, issue.18, pp.3157-3161, 2007. ,
DOI : 10.1242/jcs.03481
A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis, Science, vol.278, issue.16, pp.1473-1477, 2009. ,
DOI : 10.1074/jbc.M211976200
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy, Nature Genetics, vol.302, issue.1, pp.24-26, 2006. ,
DOI : 10.1212/WNL.56.7.979
Amyloid-? protein precursor gene expression in alzheimer's disease and other conditions, J. Alzheimers Dis, vol.28, pp.561-566, 2012. ,
APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy, Brain, vol.129, issue.11, pp.2977-2983, 2006. ,
DOI : 10.1093/brain/awl203
Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes, Neurology, vol.86, issue.18, pp.1736-1743, 2016. ,
DOI : 10.1212/WNL.0000000000002638
URL : http://www.neurology.org/content/86/18/1736.full.pdf
Frontotemporal dementia, The Lancet, vol.386, issue.10004, pp.1672-1682, 2015. ,
DOI : 10.1016/S0140-6736(15)00461-4
Epidemiology of early-onset dementia: a review of the literature, Clinical Practice & Epidemiology in Mental Health, vol.9, issue.1, pp.88-95, 2013. ,
DOI : 10.2174/1745017901309010088
The heritability and genetics of frontotemporal lobar degeneration, Neurology, vol.73, issue.18 ,
DOI : 10.1212/WNL.0b013e3181bf997a
Diagnostic criteria for fronto-temporal lobe degeneration], Encephale, vol.25, pp.612-621, 1999. ,
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, vol.51, issue.6, pp.1546-1554, 1998. ,
DOI : 10.1212/WNL.51.6.1546
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics, Brain, vol.135, issue.3, pp.794-806, 2012. ,
DOI : 10.1093/brain/aws001
URL : https://academic.oup.com/brain/article-pdf/135/3/794/5504348/aws001.pdf
Frontotemporal dementia, The British Journal of Psychiatry, vol.180, issue.2, pp.140-143, 2002. ,
DOI : 10.1192/bjp.180.2.140
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria, Movement Disorders, vol.31, issue.Suppl 2, pp.853-864, 2017. ,
DOI : 10.1523/JNEUROSCI.2600-10.2011
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy), Neurology, vol.44, issue.11, pp.2015-2019, 1994. ,
DOI : 10.1212/WNL.44.11.2015
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches, The Lancet Neurology, vol.16, issue.7, pp.552-563, 2017. ,
DOI : 10.1016/S1474-4422(17)30157-6
Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy, Neuroradiology, vol.252, issue.Pt 6, pp.431-443, 2017. ,
DOI : 10.1007/s00415-005-0791-2
Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm ,
Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies, Journal of Neurochemistry, vol.110, pp.54-70, 2016. ,
DOI : 10.1073/pnas.1315438110
Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review, Translational Neurodegeneration, vol.2, issue.1, p.8, 2013. ,
DOI : 10.1002/humu.20785
Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS, Neuron, vol.77, issue.4, pp.639-646, 2013. ,
DOI : 10.1016/j.neuron.2013.02.004
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72, Brain, vol.135, issue.3, pp.765-783, 2012. ,
DOI : 10.1093/brain/aws004
Age-related penetrance of the C9orf72 repeat expansion, Scientific Reports, vol.34, issue.1, p.2116, 2017. ,
DOI : 10.3233/JAD-121456
Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum, Trends in Neurosciences, vol.36, issue.8, pp.450-459, 2013. ,
DOI : 10.1016/j.tins.2013.04.010
Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations, Brain, vol.135, issue.3, pp.693-708, 2012. ,
DOI : 10.1093/brain/awr355
Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease, Journal of the Neurological Sciences, vol.287, issue.1-2, pp.291-293, 2009. ,
DOI : 10.1016/j.jns.2009.07.011
Genetics of Frontotemporal Dementia, Current Neurology and Neuroscience Reports, vol.130, issue.Pt 3, 2016. ,
DOI : 10.1093/brain/awl367
Exome sequencing reveals VCP mutations as a cause of familial ALS ,
Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.1, issue.4, pp.455-463, 2015. ,
DOI : 10.1016/j.dadm.2015.09.003
Impact of harmonization of collection tubes on Alzheimer's disease diagnosis, Alzheimer's & Dementia, vol.10, issue.5, pp.390-394, 2014. ,
DOI : 10.1016/j.jalz.2013.06.008
in humans, Annals of Neurology, vol.111, issue.3, pp.512-519, 2006. ,
DOI : 10.1172/JCI200317527
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of ,
Decreased CSF amyloid ??42 and normal tau levels in dementia with Lewy bodies, Neurology, vol.54, issue.9, pp.1875-1876, 2000. ,
DOI : 10.1212/WNL.54.9.1875
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J Neural Transm, vol.107, pp.563-579, 2000. ,
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, vol.289, pp.2094-2103, 2003. ,
ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst Rev, vol.3, p.10803, 2017. ,
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, The Lancet Neurology, vol.13, issue.6 ,
DOI : 10.1016/S1474-4422(14)70090-0
Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer???s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors, Journal of Alzheimer's Disease, vol.42, issue.Suppl 1, pp.625-644, 2016. ,
DOI : 10.1159/000448394
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neuroscience Letters, vol.297, issue.3, pp.187-190, 2001. ,
DOI : 10.1016/S0304-3940(00)01697-9
CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma, PLoS ONE, vol.41, issue.5, p.33606, 2012. ,
DOI : 10.1371/journal.pone.0033606.t003
Total and phosphorylated tau protein as biological markers of Alzheimer???s disease, Experimental Gerontology, vol.45, issue.1, pp.30-40, 2010. ,
DOI : 10.1016/j.exger.2009.10.010
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815003/pdf
Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease, Archives of General Psychiatry, vol.61, issue.1, pp.95-102, 2004. ,
DOI : 10.1001/archpsyc.61.1.95
A diagnostic scale for Alzheimer???s disease based on cerebrospinal fluid biomarker profiles, Alzheimer's Research & Therapy, vol.6, issue.3, p.38, 2014. ,
DOI : 10.1186/alzrt267
Analysis of Combined CSF Biomarkers in AD Diagnosis, Clinical Laboratory, vol.60, issue.04/2014, pp.629-634, 2014. ,
DOI : 10.7754/Clin.Lab.2013.130440
Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease, PLoS ONE, vol.4, issue.7 ,
DOI : 10.1371/journal.pone.0006294.t002
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease, Frontiers in Aging Neuroscience, vol.5, 2013. ,
DOI : 10.3389/fnagi.2013.00006
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI, Acta Neuropathologica, vol.46, issue.5, pp.597-609, 2011. ,
DOI : 10.1258/acb.2009.008232
CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, vol.70, issue.Issue 19, Part 2 ,
DOI : 10.1212/01.wnl.0000311445.21321.fc
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707002/pdf
Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses, Alzheimer's & Dementia, vol.6, issue.2, pp.104-109, 2010. ,
DOI : 10.1016/j.jalz.2009.12.005
Comparison of Cerebrospinal Fluid Levels of Tau and A?? 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms, Archives of Neurology, vol.69, issue.8, pp.1018-1025, 2012. ,
DOI : 10.1001/archneurol.2012.26
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed ,
TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis, Archives of Neurology, vol.65, issue.11, pp.1481-1487, 2008. ,
DOI : 10.1001/archneur.65.11.1481
Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration, Neurology, vol.71, issue.16, pp.1235-1239, 2008. ,
DOI : 10.1212/01.wnl.0000325058.10218.fc
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study, Alzheimer's & Dementia, vol.11, issue.11, pp.1306-1315, 2015. ,
DOI : 10.1016/j.jalz.2014.12.006
Age and diagnostic performance of Alzheimer disease CSF biomarkers, Neurology, vol.78, issue.7 ,
DOI : 10.1212/WNL.0b013e3182477eed
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280049/pdf
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort, Neurology, vol.78, issue.1, pp.47-54, 2012. ,
DOI : 10.1212/WNL.0b013e31823ed0f0
A prediction model to calculate probability of Alzheimer???s disease using cerebrospinal fluid biomarkers, Alzheimer's & Dementia, vol.9, issue.3, pp.262-268, 2013. ,
DOI : 10.1016/j.jalz.2012.01.010
Amyloid-??(1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease, Clinical Chemistry, vol.56, issue.2, pp.248-253, 2010. ,
DOI : 10.1373/clinchem.2009.130518
The cerebrospinal fluid ???Alzheimer profile???: Easily said, but what does it mean?, Alzheimer's & Dementia, vol.10, issue.6, pp.713-723, 2014. ,
DOI : 10.1016/j.jalz.2013.12.023
Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability, Clinica Chimica Acta, vol.449, pp.9-15, 2015. ,
DOI : 10.1016/j.cca.2015.05.024
Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid, International Journal of Alzheimer's Disease, vol.309, issue.6955, 2010. ,
DOI : 10.1258/acb.2009.008232
URL : https://doi.org/10.4061/2010/986310
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases, Acta Neuropathologica, vol.7, issue.4, pp.23-35, 2012. ,
DOI : 10.1016/j.jalz.2010.08.233
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Annals of Neurology, vol.160, issue.5, pp.721-729, 2005. ,
DOI : 10.1016/S0002-9440(10)61154-6
Cerebrospinal Fluid Tau and ??-Amyloid, Archives of Neurology, vol.60, issue.12, pp.1696-1702, 2003. ,
DOI : 10.1001/archneur.60.12.1696
URL : http://archneur.jamanetwork.com/data/journals/neur/13548/noc30071.pdf
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiology of Aging, vol.29, issue.8, pp.1143-1159, 2008. ,
DOI : 10.1016/j.neurobiolaging.2007.02.016
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases, PLOS Medicine, vol.21, issue.6, p.1002270, 2017. ,
DOI : 10.1371/journal.pmed.1002270.s002
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update, Acta Neuropathologica, vol.323, issue.1, pp.1-4, 2010. ,
DOI : 10.1007/s00401-004-0882-7
Preanalytical guidelines for clinical proteomics investigation of biological fluids], Ann. Biol. Clin. (Paris), vol.67, pp.629-639, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00444355
Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid ?((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop, Int J Alzheimers Dis, 2010. ,
Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation, Caspian J Intern Med, vol.4, pp.627-635, 2013. ,
Late-onset behavioral variant of frontotemporal lobar degeneration??versus Alzheimer's disease: Interest of cerebrospinal fluid??biomarker??ratios, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.1, issue.3, pp.371-379, 2015. ,
DOI : 10.1016/j.dadm.2015.06.004
Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer???s Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors, Journal of Alzheimer's Disease, vol.42, issue.Suppl 1, pp.625-644, 2016. ,
DOI : 10.1159/000448394
Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P, Neurochemistry International, vol.55, issue.4, pp.214-218, 2009. ,
DOI : 10.1016/j.neuint.2009.02.017
Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein, Journal of Alzheimer's Disease, vol.6, issue.3, pp.905-913, 2016. ,
DOI : 10.1186/s13195-014-0072-3
Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric??disorders, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.7, pp.99-106, 2017. ,
DOI : 10.1016/j.dadm.2017.01.009
URL : https://doi.org/10.1016/j.dadm.2017.01.009
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age, JAMA Neurology, vol.72, issue.9, pp.1029-1042, 2015. ,
DOI : 10.1001/jamaneurol.2015.1285
URL : http://archneur.jamanetwork.com/data/journals/neur/934389/noi150034.pdf
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values, Clin. Chem, vol.47, pp.1776-1781, 2001. ,
Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis, The Lancet Neurology, vol.14, issue.3, pp.253-262, 2015. ,
DOI : 10.1016/S1474-4422(14)70324-2
Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis, Neurology, vol.83, issue.3, pp.253-260, 2014. ,
DOI : 10.1212/WNL.0000000000000596
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117367/pdf
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease, Science Translational Medicine, vol.53, issue.3, pp.226-256, 2014. ,
DOI : 10.2307/2533558
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038930/pdf
Biomarkers in Sporadic and Familial Alzheimer???s Disease, Journal of Alzheimer's Disease, vol.6, issue.102, pp.291-317, 2015. ,
DOI : 10.1126/scitranslmed.3007941
Cerebrospinal fluid biomarkers of Alzheimer???s disease, Biomarkers in Medicine, vol.27, issue.1, pp.51-63, 2010. ,
DOI : 10.1002/ana.21623
Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, vol.1, issue.4, pp.403-411, 2015. ,
DOI : 10.1016/j.dadm.2015.09.002
Longitudinal changes of CSF biomarkers in memory clinic patients, Neurology, vol.69, issue.10, pp.1006-1011, 2007. ,
DOI : 10.1212/01.wnl.0000271375.37131.04
Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults, Archives of Neurology, vol.67, issue.2, pp.217-223, 2010. ,
DOI : 10.1001/archneurol.2009.316
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, The Lancet Neurology, vol.12, issue.2, pp.207-216, 2013. ,
DOI : 10.1016/S1474-4422(12)70291-0
Longitudinal changes of CSF biomarkers in Alzheimer's disease, J. Alzheimers Dis, vol.25, pp.583-594, 2011. ,
Cognitive function in very old men does not correlate to biomarkers of Alzheimer???s disease, BMC Geriatrics, vol.9, issue.1, p.208, 2017. ,
DOI : 10.1016/j.jalz.2012.11.011
Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation, Acta Neuropathologica Communications, vol.10, issue.1, 2016. ,
DOI : 10.1002/glia.22453
URL : https://hal.archives-ouvertes.fr/inserm-01346896
APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer???s disease, Molecular Psychiatry, vol.37, issue.7, pp.916-924, 2016. ,
DOI : 10.1016/j.neubiorev.2013.10.010
A 2-process model for neuropathology of Alzheimer's disease, Neurobiology of Aging, vol.35, issue.2, pp.301-308, 2014. ,
DOI : 10.1016/j.neurobiolaging.2013.08.007
Alzheimer???s disease cerebrospinal fluid biomarker in cognitively normal subjects, Brain, vol.138, issue.9, pp.2701-2715, 2015. ,
DOI : 10.1093/brain/awv199
URL : https://academic.oup.com/brain/article-pdf/138/9/2701/13800509/awv199.pdf
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 ??-Amyloid Measures Across the Spectrum of Alzheimer Disease, JAMA Neurology, vol.72, issue.5, pp.571-581, 2015. ,
DOI : 10.1001/jamaneurol.2014.4829
French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study, J. Alzheimers Dis, vol.34, pp.297-305, 2008. ,
Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis, Clinical Chemistry, vol.58, issue.4, pp.787-789, 2012. ,
DOI : 10.1373/clinchem.2011.178368
URL : https://hal.archives-ouvertes.fr/hal-00965203
Clinical validity of cerebrospinal fluid A??42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiology of Aging, vol.52, pp.196-213, 2017. ,
DOI : 10.1016/j.neurobiolaging.2016.02.034
Decreased sA?PP?, A?38, and A?40 cerebrospinal fluid levels in frontotemporal dementia, J. Alzheimers Dis, vol.26, pp.553-563, 2011. ,
Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer's Disease, Dementia and Geriatric Cognitive Disorders, vol.2, issue.1, pp.1-5, 2012. ,
DOI : 10.1038/nm0896-864
SORL1 rare variants: a major risk factor for familial early-onset Alzheimer???s disease, Molecular Psychiatry, vol.21, issue.6, pp.831-836, 2016. ,
DOI : 10.1038/nature12975